Working Paper Review Version 1 This version is not peer-reviewed

Current Genetic and Epigenetic Targeting Therapy for Pediatric Acute Lymphoblastic Leukemia

Version 1 : Received: 30 September 2021 / Approved: 1 October 2021 / Online: 1 October 2021 (12:23:33 CEST)

How to cite: Xu, H.; Yu, H.; Jin, R.; Wu, X.; Chen, H. Current Genetic and Epigenetic Targeting Therapy for Pediatric Acute Lymphoblastic Leukemia. Preprints 2021, 2021100018 Xu, H.; Yu, H.; Jin, R.; Wu, X.; Chen, H. Current Genetic and Epigenetic Targeting Therapy for Pediatric Acute Lymphoblastic Leukemia. Preprints 2021, 2021100018

Abstract

Acute lymphoblastic leukemia is the most common malignancy in children and is characterized by numerous genetic and epigenetic abnormalities. Epigenetic mechanisms, which involve DNA methylations and histone modifications, result in the heritable silencing of genes without a change in their coding sequence. Emerging studies are increasing our understanding of the epigenetic role of leukemogenesis and have demonstrated the potential of DNA methylations and histone modifications as a biomarker for lineage and subtypes classification, predicting relapse, and disease progression in ALL. Epigenetic abnormalities are relatively reversible when treated with some small molecule-based agents compared to genetic alterations. In this review, we conclude the genetic and epigenetic characteristics in ALL and discuss the future role of DNA methylation and histone modifications in predicting relapse, finally focus on the individual and precision therapy targeting epigenetic alterations.

Keywords

Pediatric Acute Lymphoblastic Leukemia; Genomics; Epigenetics; Targeted Therapy

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.